Urolift Before SBRT to Try to Lower Urinary Side Effects in Men with BPH and Prostate Cancer
Official title: Reduction of Urinary Toxicity of Stereotactic Body Radiation Therapy (SBRT) With Prostatic Urethral Lift (Urolift)
Run by Northwell Health · NCT05148156 · Data updated 2026-11-12
This study tests whether doing Urolift before SBRT can lessen urinary side effects for men with BPH and prostate cancer needing radiation therapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 99 Years |
| Sex | Men only |
| Enrollment | 20 (estimated) |
| Sponsor | Northwell Health Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Syosset, New York) |
| Status | Recruiting |
| Started | February 11, 2026 |
| Main results expected | September 2027 |
| Study ends | March 2028 |
| Registry record updated | September 29, 2026 |
| Trial ID | NCT05148156 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men aged 50–99 with BPH, a prostate cancer diagnosis requiring SBRT, adequate prostate volume (30–80 ml), and no middle lobe obstruction who can consent and complete questionnaires.
✕Probably not a fit
Patients with very high baseline urinary symptoms, incompatible anatomy, recent urethral injuries, or plans for concurrent experimental therapies may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study explores whether a pre-SBRT Urolift procedure reduces urinary toxicity in men with benign prostatic hyperplasia who require stereotactic body radiation therapy for prostate cancer. Patients will undergo a Urolift procedure prior to SBRT and will be monitored for urinary symptoms and quality of life. The trial builds on prior evidence that Urolift improves urinary function and medication needs in BPH patients. Outcomes include urinary frequency, dysuria, nocturia, and patient-reported quality of life. The study is conducted at Northwell Health with collaboration from NeoTract, Inc. and Teleflex.
Why it matters
Potential benefit: If successful, patients may experience fewer urinary symptoms and better quality of life during and after SBRT.
How similar studies have gone: Previous data suggest Urolift can improve urinary symptoms and reduce medication use, supporting potential benefit in this pre-SBRT setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject is 50 - 99 years of age * Subject has provided informed consent * Subject has diagnosis of prostate cancer requiring SBRT * Subject is able to complete self-administered questionnaires * Subject is a surgical candidate for Urolift * Subject has a diagnosis of BPH * Medical record documentation of prostate volume from 30-80 ml by TRUS * Absence of a middle lobe Exclusion Criteria: * Life expectancy \< 2 years * Currently enrolled in or plans to enroll in any concurrent drug or device study * Concurrent androgen deprivation therapy * Has an active infection (e.g., urinary tract infection or prostatitis) * Diagnosis of or has received treatment for chronic prostatitis or chronic pelvic pain syndrome (e.g., nonbacterial chronic prostatitis) * Subject has been diagnosed with a urethral stricture or bladder neck contracture within the last 180 days * Subject has been diagnosed with 2 or more urethral strictures and/or bladder neck contractures within 5 years * Diagnosis of lichen sclerosis * Neurogenic bladder or other neurologic disorder that affects bladder function * Diagnosis of polyneuropathy (e.g., diabetic) * History of lower urinary tract surgery * Subject has diagnosis of stress urinary incontinence that requires treatment or daily pad or device use * Subject has been catheterized or has a PVR \> 400 ml in the 14 days prior to the surgical procedure * Current diagnosis of bladder stones
Where it's running
-
Northwell Health
Syosset, New York, United States Recruiting
Study contacts
- Principal investigator: Bilal Chughtai, MD — Northwell Health
- Study coordinator: Jennifer Polo, CCRC
- Email: jpolo1@northwell.edu
- Phone: 516-628-5910
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sonablate HIFU Registry for Prostate Cancer and BPH
This registry collects real-world data from men treated with Sonablate HIFU to see how well it works and how it affects urinary and sexual function over the long term.
-
Tamsulosin alone vs. tamsulosin with tadalafil for troublesome urinary symptoms from enlarged prostate
This study tests whether adding tadalafil to tamsulosin helps men with BPH see better urinary symptoms and quality of life, using two tadalafil doses over 12 weeks.
-
MRI-DTI look at the urethral sphincter ring and prostate base shape
This imaging study tests how the male urethral internal sphincter ring appears on MRI-DTI and how it relates to prostate base morphology in men undergoing clinically indicated MRI.
-
Tamsulosin With or Without Tadalafil for a Trial Without Catheter After Acute Urinary Retention
This study tests whether adding tadalafil to tamsulosin helps men with a first episode of acute urinary retention due to enlarged prostate pass urine without needing a catheter.
-
Tamsulosin dose change or switch to silodosin before catheter removal in men with BPH-related acute urinary retention
This trial tests whether continuing tamsulosin, increasing its dose, or switching to silodosin helps men with BPH-related acute urinary retention go without a catheter after seven days.
-
Water Vapor Therapy vs Ejaculation-Sparing Enucleation for Benign Prostatic Hyperplasia
This study tests whether Water Vapor Thermal Therapy (Rezum) or an ejaculation-sparing enucleation procedure better helps sexually active men with bothersome BPH symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.